Export

ATC codes: N03AX14
EMLc
Indication
Status epilepticus ICD11 code: 8A66
INN
Levetiracetam
Medicine type
Chemical agent
List type
Complementary (EML)
(EMLc)
Formulations
Parenteral > General injections > IV: 500 mg per 5 mL in 5 mL vial ; 5 mg per mL in 100 mL bag ; 10 mg per mL in 100 mL bag ; 15 mg per mL in 100 mL bag
EML status history
First added in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the inclusion of oral levetiracetam on the core list of the EML and EMLc for the treatment of focal-onset and generalized-onset seizures in adults in children. The Committee also recommended the inclusion of parenteral levetiracetam on the complementary list of the EML and EMLc for use in the management of benzodiazepine-refractory status epilepticus. These recommendations were made based on evidence of effectiveness and safety, and in recognition of the need for treatment strategies for people with epilepsy to be individualized taking into account multiple factors including, but not limited to, pregnancy and patient preferences, seizure type, co-morbidities, and concomitant use of other medications. These recommendations are also aligned with expected recommendations in the updated WHO Mental Health Gap Action Programme (mhGAP) guidelines.